Charles N. York II Sells 2,675 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Free Report) CFO Charles N. York II sold 2,675 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $16.08, for a total value of $43,014.00. Following the transaction, the chief financial officer now owns 224,868 shares in the company, valued at approximately $3,615,877.44. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Day One Biopharmaceuticals Stock Up 0.9 %

Shares of Day One Biopharmaceuticals stock opened at $16.17 on Friday. The company has a 50-day simple moving average of $15.44 and a two-hundred day simple moving average of $14.46. Day One Biopharmaceuticals, Inc. has a 52-week low of $9.67 and a 52-week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DAWN shares. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, May 7th. Needham & Company LLC reissued a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, May 7th. The Goldman Sachs Group cut their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Finally, Piper Sandler reissued an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Get Our Latest Analysis on Day One Biopharmaceuticals

Institutional Trading of Day One Biopharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Quest Partners LLC bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at $29,000. Quintet Private Bank Europe S.A. lifted its stake in Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after acquiring an additional 1,000 shares during the period. Amalgamated Bank boosted its holdings in shares of Day One Biopharmaceuticals by 35.7% during the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after acquiring an additional 2,268 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Day One Biopharmaceuticals by 352.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock worth $147,000 after acquiring an additional 7,841 shares during the period. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Day One Biopharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after purchasing an additional 2,554 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

(Get Free Report)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

See Also

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.